Results for the substance vonicog alfa

Vonicog alfa is a recombinant von Willebrand factor used for the treatment and prevention of bleeding episodes in patients with von Willebrand disease, a genetic blood clotting disorder caused by a deficiency or dysfunction of von Willebrand factor. It works by replacing the missing or defective factor, facilitating platelet adhesion and blood clot formation.

Vonicog alfa is administered intravenously, usually prior to surgical procedures or during acute bleeding episodes. The dosage and frequency of administration are adjusted based on the severity of the disease and the patient's response.

Common side effects include injection site reactions, headaches, nausea, and fever. In rare cases, severe allergic reactions or the development of antibodies against von Willebrand factor may occur, potentially reducing the treatment's effectiveness.

Patients receiving vonicog alfa should be regularly monitored for von Willebrand factor levels and signs of adverse reactions. The medication is an effective and safe option for managing bleeding episodes in patients with von Willebrand disease.